SGEN - Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst | Benzinga
RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a price target of $7.
Last month, Pyxis Oncology acquired Apexigen Inc., focused on discovering and developing antibody therapeutics for oncology, in an all-stock transaction valued at approximately $10.7 million.
The combined company is positioned at the forefront of ADC innovation with a platform.
Analysts Leonid Timashev and Brian Abrahams note Pyxis Oncology's diverse oncology assets, incorporating a proven ADC platform from Pfizer Inc (NYSE: PFE) and I/O assets that ...